Inotiv(US:NOTV) Globenewswire·2025-11-17 21:05Core Insights - Inotiv, Inc. anticipates fourth quarter 2025 revenue between $137.5 million and $138.5 million, reflecting a year-over-year improvement and aligning with expectations [1][2] - The company expects full year 2025 revenue to be in the range of $512.5 million to $513.5 million [1][6] - The Discovery and Safety Assessment (DSA) services business experienced a 60% growth compared to the same period last year, with a book-to-bill ratio of approximately 1.08x for Q4 FY 2025 [2][6] Preliminary Financial Results - Preliminary expected revenue for Q4 FY 2025 is projected at $137.5 million to $138.5 million [1][6] - Full year 2025 revenue is anticipated to be between $512.5 million and $513.5 million [1][6] - DSA backlog is expected to be approximately $138.0 million as of September 30, 2025, an increase from $129.9 million a year prior [6] Company Presentation - Robert Leasure Jr., President and CEO, will present at the Jefferies Global Healthcare Conference on November 18, 2025, at 11:00 AM GMT [4] - The presentation will be accessible via a live webcast, with a replay available on the company's website [4] Company Overview - Inotiv, Inc. is a leading contract research organization focused on nonclinical and analytical drug discovery and development services [5][7] - The company aims to enhance efficiency, improve data quality, and reduce costs associated with bringing new drugs and medical devices to market [5]